Oesophageal Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged between 18 and 75 years (both men and women, with an aim for roughly equal numbers of each).
- People who have been diagnosed with stage II or III squamous cell cancer of the oesophagus (a specific type of oesophageal cancer), confirmed by tissue testing, and whose cancer has been assessed as not suitable for surgery.
- People who are planned to receive a treatment sequence of: immune-boosting therapy combined with chemotherapy first, then intensive radiation and chemotherapy combined with immune-boosting therapy, and finally ongoing immune-boosting therapy afterwards.
- People who have a good general level of physical functioning, rated 0 or 1 on a standard medical scale (meaning fully active or restricted in strenuous activity but able to carry out light work).
- People whose blood, liver, and kidney results meet the required levels — including healthy white blood cell counts, platelet counts, and haemoglobin levels, as well as liver and kidney function within acceptable ranges (confirm with trial site for specific values).
- Women who could become pregnant must have had a negative pregnancy test within 7 days before starting treatment.
- People who understand the trial and have signed a consent form agreeing to take part.
Who may not be able to join:
- People who have been diagnosed with or treated for any other cancer in the 5 years before the trial begins.
- People whose oesophageal cancer is of a different type than squamous cell carcinoma — for example, adenocarcinoma or mixed types.
- People who have an unstable or serious ongoing health condition, such as an uncontrolled active infection, uncontrolled high blood pressure, unstable chest pain, recent heart attack (within 6 months), moderate-to-severe heart failure, significant irregular heartbeat requiring medication, or serious liver, kidney, or metabolic disease.
- People with a known or suspected active autoimmune disease (a condition where the immune system attacks the body's own tissues).
- People who have previously received certain types of immune checkpoint or T-cell targeting treatments (such as anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-CTLA-4 therapies).
- People who are known to be HIV-positive or to have AIDS.
- Women who are pregnant or currently breastfeeding.
- People considered unsuitable for the trial for other reasons, as determined by the treating doctor at the trial site.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Wenbin Shen, PhD, Hebei Medical University Fourth Hospital
Phone: +86 15831183879
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Correlations of minimal residual disease (MRD) and efficacy
Can't join this trial?
Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.